VRTX:NGS-Vertex Pharmaceuticals Incorporated

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 194.70

Change

0.00 (0.00)%

Market Cap

USD 49.76B

Volume

2.15M

Average Target Price

USD 203.72 (4.63%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

N/A

USD 129.92B
GILD Gilead Sciences Inc.

N/A

USD 89.49B
BIIB Biogen Inc.

N/A

USD 67.98B
CELG Celgene Corporation

N/A

USD 60.41B
SHPG Shire plc

N/A

USD 54.84B
REGN Regeneron Pharmaceuticals Inc.

N/A

USD 45.33B
ALXN Alexion Pharmaceuticals Inc.

N/A

USD 26.11B
BMRN BioMarin Pharmaceutical Inc.

N/A

USD 17.39B
INCY Incyte Corporation

N/A

USD 16.69B
GRFS Grifols S.A.

N/A

USD 13.24B

ETFs Containing VRTX

BBH VanEck Vectors Biotech ET.. 5.08 % 0.35 %

N/A

USD 0.43B
PBE Invesco Dynamic Biotech &.. 5.04 % 0.59 %

N/A

USD 0.28B
FMDG Fieldstone Merlin Dynamic.. 4.50 % 0.80 %

N/A

N/A
IBB iShares Nasdaq Biotechnol.. 4.16 % 0.47 %

N/A

USD 8.27B
PXLG Invesco Russell Top 200 P.. 4.07 % 0.39 %

N/A

USD 0.25B
FBT First Trust Amex Biotech .. 3.62 % 0.56 %

N/A

USD 2.73B
LNGR Global X Longevity Themat.. 3.14 % 0.52 %

N/A

N/A
QGRO American Century STOXX U... 2.07 % 0.00 %

N/A

N/A
RPG Invesco S&P 500 Pure Grow.. 1.73 % 0.35 %

N/A

USD 2.16B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.49% 60% D- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.49% 60% D- 78% C+
Trailing 12 Months  
Capital Gain 23.25% 84% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.25% 84% B 88% B+
Trailing 5 Years  
Capital Gain 127.77% 84% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 127.77% 84% B 86% B
Average Annual (5 Year Horizon)  
Capital Gain 24.17% 72% C- 82% B-
Dividend Return 24.17% 72% C- 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.14% 57% F 27% F
Risk Adjusted Return 58.76% 91% A- 66% D
Market Capitalization 21.38B 99% A+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 76.05 2% F 4% F
Price/Book Ratio 18.53 5% F 5% F
Price / Cash Flow Ratio 10.63 3% F 7% F
Price/Free Cash Flow Ratio 46.69 3% F 9% F
Management Effectiveness  
Return on Equity 25.83% 90% A- 87% B+
Return on Invested Capital 25.28% 93% A 90% A-
Return on Assets 15.73% 97% A+ 94% A
Debt to Equity Ratio 24.25% 41% F 64% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.